Quantcast

Latest Interstitial lung disease Stories

2014-08-05 08:34:38

MORRISTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Moerae Matrix, Inc. announced today the initiation of a Phase 1 clinical trial of MMI-0100, a first-in-class inhibitor of MAPKAP Kinase 2 (MK2) being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases characterized by inflammation and fibrosis. The Phase 1 study is being conducted in the Netherlands and will evaluate the safety, tolerability and pharmacokinetics of ascending doses of MMI-0100 when given...

2014-06-10 12:30:16

CHICAGO, June 10, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry. The PFF announced its plan to establish a PFF Patient Registry, along with a PFF Care Center Network (CCN), at its biennial PFF Summit held in December 2013. "Our partnership with Biogen Idec will further enhance the PFF Patient Registry, allowing us to investigate fundamentally important questions in...

2014-05-20 12:33:47

Classifier shows promise for differentiating IPF from other interstitial lung diseases SOUTH SAN FRANCISCO, Calif., May 20, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of the first proof-of-concept data demonstrating the company's ability to develop a molecular classifier to differentiate interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and its histological hallmark, usual interstitial pneumonia (UIP). The data were...

2014-05-18 16:20:52

-- Two Phase 3 trials met primary endpoint of reduction in annual rate of lung function decline RIDGEFIELD, Conn., May 18, 2014 /PRNewswire/ -- Boehringer Ingelheim announced the results of its two pivotal Phase 3 INPULSIS(TM) trials (INPULSIS(TM)-1 and -2; NCT01335464 and NCT01335477), which were published online today in the New England Journal of Medicine (NEJM). The INPULSIS(TM) trials evaluated the efficacy and safety of nintedanib, an investigational therapy being studied in people with...

2014-05-16 08:26:34

BRISBANE, Calif., May 16, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced it will provide compassionate use of pirfenidone through a multi-center Expanded Access Program (EAP) in the United States to be conducted under InterMune's U.S. IND. Pirfenidone is an investigational therapy in the U.S. and has not been approved by the U.S. Food and Drug Administration (FDA). Expanded access programs provide a mechanism for early access to an investigational drug in the...

2014-04-21 00:20:49

SAN DIEGO, April 21, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF). Our results indicate that very small inhaled doses deliver oral-superior, but short-lived lung levels. To understand if this increased lung dose may...

2014-03-27 12:30:22

CHICAGO, March 27, 2014 /PRNewswire-USNewswire/ -- Patients with pulmonary fibrosis (PF), their caregivers, family members, and health care providers will now be able to access a centralized communications center. Established by the Pulmonary Fibrosis Foundation (PFF), the leading pulmonary fibrosis patient advocacy organization, the PFF Patient Communication Center (PCC) will be the first-ever comprehensive communication resource that will be available to the PF community. This...

2014-02-04 16:28:20

Chief Medical Officer and Chairman of the Steering Committee for the PFF Care Center Network and PFF Patient Registry Announced CHICAGO, Feb. 4, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced two key additions to their staff. Gregory P. Cosgrove, MD, has been named Chief Medical Officer and Kevin R. Flaherty, MD, MS, has been named Chairman of the Steering Committee of the PFF Care Center Network and PFF Patient Registry. "We are pleased to...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'karpos', fruit.
Related